What You Should Know
- Viome Life Sciences announced the acquisition of Circulate Health, a developer of outpatient therapeutic plasma exchange (TPE) protocols targeting healthspan extension and chronic disease management.
- The transaction bridges Viome’s molecular diagnostic, microbiome, and precision nutrition platform with Circulate’s physician-guided outpatient TPE protocols and nationwide network of partner clinics staffed by specialized nurses.
- Circulate Health Co-Founder and CEO Dr. Brad Younggren, MD, joins Viome as President of its newly formed clinical division, Viome Professional.
- Clinical research backing Circulate’s protocols includes a 2026 study in the Journal of Clinical Apheresis associating TPE with reductions in circulating microplastics in blood, alongside a 2025 Aging Cell study reporting an average 2.6-year reduction in biological age across molecular biomarker panels.
- Circulate Health was originally co-founded by Dr. Brad Younggren and Dr. Eric Verdin, CEO of the Buck Institute for Research on Aging.
Closing the Diagnostic-to-Therapeutic Loop
While high-resolution molecular assays—such as mRNA sequencing, microbiome profiling, and epigenetic biological age clocks—offer detailed visibility into systemic inflammation and cellular aging, the longevity medicine sector has historically lacked standardized, scalable clinical therapies to address those diagnostic findings.
Viome’s acquisition of Circulate Health establishes an integrated “measure, act, and measure again” operational model:
- Protocolized Outpatient TPE: Adapts therapeutic plasma exchange—a clinical procedure used in hospital neurology and immunology settings for more than 50 years—into standardized, physician-supervised outpatient protocols delivered across a network of over 200 partner clinics.
- Targeting Environmental Toxins & Biological Aging: Integrates clinical protocols backed by peer-reviewed evidence, including a 2026 study in the Journal of Clinical Apheresis demonstrating reductions in circulating blood microplastics and 2025 research in Aging Cell showing an average 2.6-year reduction in biological age across molecular biomarker panels.
- Longitudinal Biomarker Tracking: Pairs Viome’s proprietary metatranscriptomic sequencing and microbiome insights with TPE procedures, enabling care teams to establish a molecular baseline, administer targeted therapeutic plasma exchange and precision nutrition, and re-test to quantify physiological outcomes over time.
- Clinical Division Leadership: Establishes Viome PRO under the leadership of Dr. Brad Younggren, MD (co-founder and former CEO of Circulate Health), to drive enterprise clinician adoption and expand provider-facing longevity workflows.
“We don’t accept that declining health is inevitable,” said Naveen Jain, Founder of Viome. “The future of medicine isn’t treating disease. It’s making health something you can measure and improve, year after year. Acquiring Circulate is the latest step in giving patients not just answers, but precision intervention. That’s what longevity medicine should be, and we’re just getting started.”
